Evidence map›Paper›PMID 37143730›Full record

SynthesisFrontiers in endocrinology2023

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Giovanni Corrao, Annalisa Biffi, Gloria Porcu, Raffaella Ronco, Giovanni Adami, Rosaria Alvaro, Riccardo Bogini, Achille Patrizio Caputi, Luisella Cianferotti, Bruno Frediani and 14 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 1 country.

Giovanni CorraoNational Centre for Healthcare Research and Pharmacoepidemiology, Laboratory of the University of Milano-Bicocca, Milan, Italy.
Annalisa BiffiNational Centre for Healthcare Research and Pharmacoepidemiology, Laboratory of the University of Milano-Bicocca, Milan, Italy.
Gloria PorcuNational Centre for Healthcare Research and Pharmacoepidemiology, Laboratory of the University of Milano-Bicocca, Milan, Italy.
Raffaella RoncoNational Centre for Healthcare Research and Pharmacoepidemiology, Laboratory of the University of Milano-Bicocca, Milan, Italy.
Giovanni AdamiRheumatology Unit, University of Verona, Verona, Italy.
Rosaria AlvaroDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Riccardo BoginiLocal Health Unit (USL) Umbria, Perugia, Italy.
Achille Patrizio CaputiDepartment of Pharmacology, School of Medicine, University of Messina, Messina, Italy.
Luisella CianferottiItalian Bone Disease Research Foundation, Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO), Florence, Italy.
Bruno FredianiDepartment of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Davide GattiRheumatology Unit, University of Verona, Verona, Italy.
Stefano GonnelliDepartment of Medicine, Surgery and Neuroscience, Policlinico Le Scotte, University of Siena, Siena, Italy.
Giovanni IolasconDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Naples, Italy.
Andrea LenziDepartment of Experimental Medicine, Sapienza University of Rome, Viale del Policlinico, Rome, Italy.
Salvatore LeoneAMICI Onlus, Associazione Nazionale per le Malattie Infiammatorie Croniche dell'Intestino, Milan, Italy.
Raffaella MichieliItalian Society of General Medicine and Primary Care Società Italiana di Medicina Generale e delle cure primarie (SIMG), Florence, Italy.
Silvia MigliaccioDepartment of Movement, Human and Health Sciences, Foro Italico University, Rome, Italy.
Tiziana NicolettiCnAMC, Coordinamento nazionale delle Associazioni dei Malati Cronici e rari di Cittadinanzattiva, Rome, Italy.
Marco PaolettaDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Naples, Italy.
Annalisa PenniniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Eleonora PiccirilliDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
Maurizio RossiniRheumatology Unit, University of Verona, Verona, Italy.
Umberto TarantinoDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
Maria Luisa BrandiItalian Bone Disease Research Foundation, Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO), Florence, Italy.
University of Milano-Bicocca · ITUniversity of Verona · ITPoliclinico Tor Vergata · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Rome Tor Vergata · ITUniversity of Siena · ITForo Italico University of Rome · ITSapienza University of Rome · ITSocietà Italiana di Medicina Generale · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fragility fractures are a major public health concern owing to their worrying and growing burden and their onerous burden upon health systems. There is now a substantial body of evidence that individuals who have already suffered a fragility fracture are at a greater risk for further fractures, thus suggesting the potential for secondary prevention in this field. Purpose: This guideline aims to provide evidence-based recommendations for recognizing, stratifying the risk, treating, and managing patients with fragility fracture. This is a summary version of the full Italian guideline. Methods: The Italian Fragility Fracture Team appointed by the Italian National Health Institute was employed from January 2020 to February 2021 to (i) identify previously published systematic reviews and guidelines on the field, (ii) formulate relevant clinical questions, (iii) systematically review literature and summarize evidence, (iv) draft the Evidence to Decision Framework, and (v) formulate recommendations. Results: Overall, 351 original papers were included in our systematic review to answer six clinical questions. Recommendations were categorized into issues concerning (i) frailty recognition as the cause of bone fracture, (ii) (re)fracture risk assessment, for prioritizing interventions, and (iii) treatment and management of patients experiencing fragility fractures. Six recommendations were overall developed, of which one, four, and one were of high, moderate, and low quality, respectively. Conclusions: The current guidelines provide guidance to support individualized management of patients experiencing non-traumatic bone fracture to benefit from secondary prevention of (re)fracture. Although our recommendations are based on the best available evidence, questionable quality evidence is still available for some relevant clinical questions, so future research has the potential to reduce uncertainty about the effects of intervention and the reasons for doing so at a reasonable cost.

Indexed as

Osteoporotic FracturesContinuity of Patient CareHumansRisk AssessmentSecondary Preventionevidence-based guidelinefragility fracturegradesecondary preventionsystematic review

Identifiers

PMID37143730
PMCPMC10151776
OpenAlexW4366293278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.